Milan Court Suspends Board Appointment, Reinstates Prior Directors
GNTA is trading near its 52-week low of $0.55 (15% above the low).
Summary
A Milan tribunal issued an interim order suspending the board appointment resolution passed at the June 29 shareholders' meeting, pending the outcome of litigation. The prior board is reinstated and Pierluigi Paracchi returns as chairman; the company says it will appeal. This lands in the middle of a contested governance fight — minority shareholders already went to court in October over the ATC acquisition capital increase, and that request was denied. Control of the board is now in flux while Genenta is mid-pivot from biotech to an aerospace-and-defense consolidator and carrying a €300 million capital raise authorization plus a reverse split approved in July. The Nasdaq $1.00 bid-price notice from October 21 adds pressure: a divided board complicates executing the reverse split and any capital deployment.
At the time of this announcement, GNTA was trading at $0.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.9M. The 52-week trading range was $0.55 to $10.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.